Sintx Technologies Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	10.2yrs

Recent management updates

Recent updates

CEO

Sintx Technologies has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
B. Bal	Principal Financial Officer & Chairman	12.5yrs	US$536.95k	0.00013% $ 3.8
David Truetzel	Independent Director	13.9yrs	US$124.21k	0% $ 0
Erik Stookey	Independent Director	9.8yrs	US$43.43k	0% $ 0
Jeffrey White	Independent Director	10.6yrs	US$43.43k	no data
Mark Froimson	Independent Director	5.5yrs	US$43.18k	0% $ 0
Giuseppe Pezzotti	Member of Scientific Advisory Board	8.9yrs	no data	no data

10.2yrs

Average Tenure

63yo

Average Age

Experienced Board: 1110's board of directors are seasoned and experienced ( 10.2 years average tenure).

Sintx Technologies Management

Management criteria checks 1/4

Key information

Recent management updates

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Insufficient new directors

Insufficient new directors

Recent updates

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3.114779 million.

Sintx Technologies, Inc. Announces Appointment of Eric K. Olson as Chief Executive Officer

Sintx Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.115475 million.

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.11 loss in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Full year 2020 earnings released: US$1.01 loss per share (vs US$4.82 loss in FY 2019)

Sintx Technologies, Inc. Announces the Fabric Technology Shown to Inactivate Upon contact SARS-CoV-2, the Virus Causing the Covid-19 Pandemic

SINTX Technologies, Inc. Submits Master Access File to FDA for Silicon Nitride-Polymer Composite Material

O2TODAY and SINTX Technologies Enter Commercialization Agreement to Fight COVID-19

Sintx Technologies Enters into Patent License Agreement with O2 Design, Inc. to Commercialize Face Masks and Mask Filter

New 90-day high: €1.79

New 90-day low: €1.30

Revenue misses expectations

Third quarter 2020 earnings released: US$0.11 loss per share

SINTX Technologies and Iwatani Group Announce Agreement to Develop Antipathogenic Surfaces to Help Prevent Spread of the Common Flu, COVID-19, and Other Viral Diseases

SINTX Technologies, Inc. Develops New Mask Fabric with Silicon Nitride

SINTX Technologies Appoints Michael Marcroft as Vice President of Business Development

Sintx Technologies, Inc. Hires Don Bray as Vice President of Business Development

First half earnings released

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $8.196 million.

New 90-day high - €2.26

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

Sintx Technologies Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $4.128 million.

CEO

Board Members

Average Tenure